|
MrMed, India’s online specialty pharmacy, announced the launch of its state-of-the-art Bengaluru cold-chain hub and announced a strategic partnership with global healthcare leader Eli Lilly, marking a significant advancement in improving access to high-quality specialty medicines across India.
The newly operational cold-chain hub is supporting the safe, seamless delivery of critical therapies including oncology, GLP-1 medications, immunology treatments, and transplant medicines. This development reinforces MrMed’s commitment to strengthening India’s specialty-medicine ecosystem by enhancing availability, affordability, and last-mile accessibility for patients who depend on advanced treatment options.
“This expansion marked an important milestone in our mission to strengthen India’s specialty-medicine ecosystem. Our partnership with Eli Lilly enables us to reach more patients with life-saving therapies, supported by enhanced cold-chain capabilities” said Devashish Singh, co-founder & CEO, MrMed.
With diabetes and obesity now affecting over 100 million people in India, the need for reliable access to advanced therapies is more urgent than ever. The MrMed’s Bengaluru cold-chain hub is already reducing delivery timelines within the city while enabling faster dispatches across Karnataka, Tamil Nadu, Telangana, and Kerala.
“Our Bengaluru cold-chain hub represents a significant step toward strengthening India’s specialty-medicine supply network. As demand for advanced therapies continues to rise, our priority is ensuring patients receive critical treatments safely, reliably, and on time. Our collaboration with Eli Lilly enhances this effort by combining their global expertise with our expanding distribution capabilities,” said Saurab Jain, co-founder & CBO, MrMed.
The launch highlights the growing importance of robust cold-chain infrastructure in maintaining the quality and efficacy of specialty medicines. MrMed’s partnership with Eli Lilly demonstrates a shared commitment to improving patient outcomes through innovation, accessibility, and supply-chain excellence, said the company note.
Through this collaboration, MrMed has strengthened its ability to distribute temperature-sensitive, genuine medicines with greater precision and reliability. Eli Lilly’s global leadership in innovative treatments, combined with MrMed’s expanded cold-chain network, is expected to significantly improve reach, affordability, and continuity of care for patients across India, according to the communication note.
|